Department of Orthopaedics, Affiliated Hospital of Intergrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 Jiangsu, China.
Department of Cardiology, Affiliated Hospital of Intergrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028 Jiangsu, China.
Biomed Res Int. 2020 Oct 17;2020:4751756. doi: 10.1155/2020/4751756. eCollection 2020.
To explore the proportion and characteristic of Chinese adults meeting (SPRINT) eligibility criteria and assess its generalizability.
Our study was based on a cross-sectional, population-based survey with a sample of 26,093 participants aged over 20 years. The SPRINT eligibility criteria were age ≥ 50 years, elevated SBP of 130 to 180 mmHg depending on the number of antihypertensive medication classes being taken, and increased cardiovascular disease (CVD) but without diabetes, history of stroke and estimated glomerular filtration rate < 20 ml/min/1.73 m, or receiving dialysis.
Overall, we estimated that 4,036 (15.5%) participants would meet the SPRINT eligibility criteria. They were generally older, likely to be female, lower educational level, tended to be more overweight, and had higher Framingham risk score compared with overall population or subjects aged ≥ 50 years. Of participants eligible for SPRINT, most (56.2%) of them were not treated for hypertension, and 542 (13.4%) were not previously considered to have hypertension or need for antihypertension therapy. Among the 11,637 adults with hypertension, 3,494 (30.0%) would potentially benefit from treatment intensification. The most common antihypertensive medication class being taken was diuretic agents.
A substantial percentage of Chinese subjects meet the SPRINT eligibility criteria. Further studies are needed to assess the cost-effectiveness from treatment intensification in Chinese setting.
探讨符合 SPRINT 入选标准的中国成年人的比例和特征,并评估其普遍性。
我们的研究基于一项横断面、基于人群的调查,样本量为 26093 名年龄在 20 岁以上的参与者。SPRINT 入选标准为年龄≥50 岁、服用 1 至 3 种降压药物时的收缩压为 130 至 180mmHg、心血管疾病(CVD)但无糖尿病、中风史和估算肾小球滤过率<20ml/min/1.73m2,或正在接受透析。
总体而言,我们估计有 4036 名(15.5%)参与者符合 SPRINT 入选标准。与总体人群或年龄≥50 岁的人群相比,他们通常年龄较大,女性居多,教育程度较低,超重的可能性更高,Framingham 风险评分更高。在符合 SPRINT 入选标准的参与者中,大多数(56.2%)未接受高血压治疗,542 名(13.4%)以前未被认为患有高血压或需要降压治疗。在 11637 名高血压患者中,3494 名(30.0%)可能受益于强化治疗。服用最多的降压药物类别是利尿剂。
相当一部分中国患者符合 SPRINT 入选标准。需要进一步研究来评估在中国人群中强化治疗的成本效益。